Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 29.0 | 41 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 28.0 | 48 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 37.0 | 34 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 28.5 | 34 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 39.0 | 37 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 43.0 | 41 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 53.0 | 30 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 39.5 | 40 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 40.0 | 33 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 55.0 | 28 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | PDGF-BB | 47.0 | 39 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 52.0 | 36 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 50.5 | 42 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 35.0 | 41 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 51.5 | 38 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 60.5 | 38 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 34.0 | 31 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 62.0 | 36 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 79.0 | 23 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 67.0 | 29 | |
N2645 | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 66.5 | 34 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 33.5 | 24 | |
RA2708 | TNF-a | 100 | ng/mL | 4 | PDGF-BB | 67.5 | 30 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 4 | PDGF-BB | 25.0 | 22 | ||||
RA2159 | IKK16 | 2.0 | uM | 4 | PDGF-BB | 27.0 | 39 |